Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59M
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
2.65M
-
Shares change
-
-939K
-
Total reported value, excl. options
-
$45.2M
-
Value change
-
-$9.75M
-
Put/Call ratio
-
0.39
-
Number of buys
-
3
-
Number of sells
-
-22
-
Price
-
$17.04
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q1 2024
28 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.65M shares
of 59M outstanding shares and own 4.5% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (1.15M shares), CITADEL ADVISORS LLC (1.11M shares), DEUTSCHE BANK AG\ (549K shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (258K shares), Bank of New York Mellon Corp (94.2K shares), Birchview Capital, LP (25.1K shares), Legal & General Group Plc (19.6K shares), JPMORGAN CHASE & CO (19.5K shares), NEW YORK STATE COMMON RETIREMENT FUND (9.51K shares), and Royal Bank of Canada (580 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.